You are here

Management of the refractory patient

A. Dignass

3-4 .Management of the refractory patient

Axel Dignass recommended testing for cytomegalovirus and Clostridium difficile which are frequently found in refractory UC. IBD care is in effect sub par due to suboptimal dosing or absent topical 5-ASA-therapy. Steroids are currently the standard therapy for refractory UC. ECCO’s international guidelines propose anti-TNF therapy or tacrolimus for second line treatment although surgical options or admission for parenteral steroid therapy could also be considered. New medications in the horizon include vedolizumab and alternative anti-TNF, among others.



Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.

IBD 13.03.2015

Visit the journal website!

Search form